A randomized, double blind, comparative, phase II/III study to evaluate the immunogenicity and safety of three formulations (15mcg without adjuvant and 7.5mcg with adjuvant and 3.75mcg with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults. - H1N1 Adult

Trial Profile

A randomized, double blind, comparative, phase II/III study to evaluate the immunogenicity and safety of three formulations (15mcg without adjuvant and 7.5mcg with adjuvant and 3.75mcg with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults. - H1N1 Adult

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 21 Aug 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top